Latest Industry Insights

Developing and manufacturing biotherapeutics at scale requires thorough analysis of the active substance’s characteristics to ensure it fulfils both efficacy and safety requirements. Analytical technologies, such as mass spectrometry, are key tools adopted in this process.

Despite hydrogen being used successfully in many labs, concerns persist about converting existing helium-based methods to hydrogen. We speak to Aaron Boice from Agilent to learn how a new technology is helping with this transition.

In a recent interview with Technology Networks, Mathew Keegan discusses how automation is already enhancing the lab experience, the challenges it faces and where it may head in the future.

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.

In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.

In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

In this interview, Gregory J. McKenzie, PhD, discusses the impact of antibiotics, the introduction of new bacteria into the microbiome and the potential of human breast milk-based therapeutics.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.